Biodesix Receives Positive Coverage from Cigna for VeriStrat Test
Biodesix' VeriStrat test is covered by Cigna
×
254 Results
Biodesix' VeriStrat test is covered by Cigna
Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
AVEO and Biodesix announce a groundbreaking partnership on ficlatuzumab
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.
Biodesix' Veristrat test is now covered by Highmark BCBS.
VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).